跳至主要内容
临床试验/ISRCTN59757862
ISRCTN59757862已完成未知

SCOT - Short Course Oncology Therapy: a study of adjuvant chemotherapy in colorectal cancer by the CACTUS and QUASAR 3 Groups

HS Greater Glasgow and Clyde0 个研究点目标入组 6,088 人开始时间: 2007年8月1日最近更新:
适应症

试验速览

阶段
未知
状态
已完成
发起方
入组人数
6,088

研究概览

简要总结

2018 Results article in https://www.ncbi.nlm.nih.gov/pubmed/29611518 results 2019 Results article in https://www.ncbi.nlm.nih.gov/pubmed/31852579 results (added 20/12/2019) 2024 Other publications in https://pubmed.ncbi.nlm.nih.gov/38865139/ Post hoc analysis (added 13/06/2024)

研究设计

研究类型
Interventional

入排标准

性别
All

入选标准

  • Current inclusion criteria as of 10/07/2014:
  • 1. Fully resected stage III colorectal cancer or high-risk stage II disease (defined as T4 disease, perforation, obstruction, less than 10 nodes examined, poorly differentiated histology or venous invasion)
  • 2. No evidence of metastatic disease
  • 3. Within 11 weeks of surgery
  • 4. World Health Organisation Performance Status (WHO PS) equals zero or one
  • 5. Greater than or equal to 18 years of age
  • 6. Life expectancy greater than 5 years
  • 7. Written informed consent
  • 8. Normal Carcinoembryonic Antigen (CEA)
  • 9. Patients with rectal cancer will be eligible unless they have had pre-op (chemotherapy) radiotherapy or are scheduled for post-op (chemotherapy) radiotherapy. Such patients must have had Total Mesorectal Excision (TME) surgery with negative (RO) resection margins
  • Previous inclusion criteria:
  • 1. Fully resected stage III colorectal cancer or high-risk stage II disease (defined as T4 disease, perforation, obstruction, less than 10 nodes examined, poorly differentiated histology or venous invasion)
  • 2. No evidence of metastatic disease
  • 3. Within eight weeks of surgery
  • 4. World Health Organisation Performance Status (WHO PS) equals zero or one
  • 5. Greater than or equal to 18 years of age
  • 6. Life expectancy greater than five years
  • 7. Written informed consent
  • 8. Normal Carcinoembryonic Antigen (CEA)
  • 9. Patients with rectal cancer will be eligible unless they have had pre-op (chemotherapy) radiotherapy or are scheduled for post-op (chemotherapy) radiotherapy. Such patients must have had Total Mesorectal Excision (TME) surgery with negative (RO) resection margins

排除标准

  • 1. Previous chemotherapy
  • 2. Previous abdomino-pelvic radiotherapy
  • 3. Moderate/severe renal impairment (Glomerular Filtration Rate [GFR] less than 30 ml/min)
  • 4. Absolute neutrophil count less than 1.5 x 10^9
  • 5. Platelet count less than 100 x 10^9
  • 6. Haemoglobin less than 9 g/dl
  • 7. Liver function tests greater than 2.5 Upper Limit of Normal (ULN)
  • 8. Clinically significant cardiovascular disease
  • 9. Pregnancy/lactation or of childbearing potential not using adequate contraception
  • 10. Previous malignancy
  • 11. Known Dihydropyrimidine Dehydrogenase (DPD) deficiency
  • In addition, for the 3-month randomisation point, only patients deemed to be fit to continue treatment will be randomised.

研究者

发起方
HS Greater Glasgow and Clyde

相似试验